Thermal stability threshold for amyloid formation in light chain amyloidosis

International Journal of Molecular Sciences

Volumn 14, Issue 11, 2013, Pages 22604-22617

  Poshusta, Tanya L ^a   Katoh, Nagaaki ^b   Gertz, Morie A ^c   Dispenzieri, Angela ^c   Ramirez Alvarado, Marina ^a  

^a MAYO GRADUATE SCHOOL   (United States)

^b SHINSHU UNIVERSITY   (Japan)

^c MAYO CLINIC   (United States)

Author keywords

Amyloid fibril formation; Hematologic response; Immunoglobulin light chain; Light chain amyloidosis; Organ response; Partially folded states; Thermodynamic stability

Indexed keywords

AMYLOID; IMMUNOGLOBULIN LIGHT CHAIN;

AMINO ACID SEQUENCE; AMYLOIDOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; KIDNEY DISEASE; LIGHT CHAIN AMYLOIDOSIS; MOLECULAR PATHOLOGY; PH; PROTEIN FOLDING; PROTEIN STABILITY; PROTEIN SYNTHESIS; SEQUENCE ALIGNMENT; THERMOSTABILITY;

AMYLOID; AMYLOIDOSIS; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; KINETICS; PROTEIN FOLDING; PROTEIN STABILITY; SEQUENCE ANALYSIS, PROTEIN;

EID: 84887553998     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms141122604     Document Type: Article

References (21)

1. Kyle, R. A.; Gertz, M. A. Primary systemic amyloidosis: Clinical and laboratory features in 474 cases. Semin. Hematol. 1995, 32, 45-59.
2. Dispenzieri, A.; Gertz, M. A.; Buadi, F. What do I need to know about immunoglobulin light chain (AL) amyloidosis? Blood Rev. 2012, 26, 137-154.
3. Gertz, M. A. Immunoglobulin light chain amyloidosis: 2013 update on diagnosis, prognosis, and treatment. Am. J. Hematol. 2013, 88, 416-425.
4. Kumar, S.; Dispenzieri, A.; Lacy, M. Q.; Hayman, S. R.; Buadi, F. K.; Colby, C.; Laumann, K.; Zeldenrust, S. R.; Leung, N.; Dingli, D.; et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J. Clin. Oncol. 2012, 30, 989-995.
5. Gatt, M. E.; Palladini, G. Light chain amyloidosis 2012: A new era. Br. J. Haematol. 2013, doi: 10. 1111/bjh. 12191.
6. Stevens, F. J. Four structural risk factors identify most fibril-forming kappa light chains. Amyloid 2000, 7, 200-211.
7. Poshusta, T. L.; Sikkink, L. A.; Leung, N.; Clark, R. J.; Dispenzieri, A.; Ramirez-Alvarado, M. Mutations in specific structural regions of immunoglobulin light chains are associated with free light chain levels in patients with AL amyloidosis. PLoS One 2009, 4, e5169.
8. Blancas-Mejia, L. M.; Tellez, L. A.; del Pozo-Yauner, L.; Becerril, B.; Sanchez-Ruiz, J. M.; Fernandez-Velasco, D. A. Thermodynamic and kinetic characterization of a germ line human lambda6 light-chain protein: The relation between unfolding and fibrillogenesis. J. Mol. Biol. 2009, 386, 1153-1166.
9. DiCostanzo, A. C.; Thompson, J. R.; Peterson, F. C.; Volkman, B. F.; Ramirez-Alvarado, M. Tyrosine residues mediate fibril formation in a dynamic light chain dimer interface. J. Biol. Chem. 2012, 287, 27997-28006.
10. Khurana, R.; Gillespie, J. R.; Talapatra, A.; Minert, L. J.; Ionescu-Zanetti, C.; Millett, I.; Fink, A. L. Partially folded intermediates as critical precursors of light chain amyloid fibrils and amorphous aggregates. Biochemistry 2001, 40, 3525-3535.
11. McLaughlin, R. W.; De Stigter, J. K.; Sikkink, L. A.; Baden, E. M.; Ramirez-Alvarado, M. The effects of sodium sulfate, glycosaminoglycans, and Congo red on the structure, stability, and amyloid formation of an immunoglobulin light-chain protein. Protein Sci. 2006, 15, 1710-1722.
12. Sikkink, L. A.; Ramirez-Alvarado, M. Salts enhance both protein stability and amyloid formation of an immunoglobulin light chain. Biophys. Chem. 2008, 135, 25-31.
13. Blancas-Mejía, L. M.; Tischer, A.; Thompson, J. R.; Tai, J.; Wang, L.; Auton, M.; Ramirez-Alvarado, M. Kinetic control in protein folding for light chain amyloidosis and the differential effects of somatic mutations. J. Mol. Biol. 2013, doi: 10. 1016/j. jmb. 2013. 10. 016.
14. Blancas-Mejia, L. M.; Ramirez-Alvarado, M. Systemic amyloidoses. Annu. Rev. Biochem. 2013, 82, 745-774.
15. Martin, D. J.; Ramirez-Alvarado, M. Comparison of amyloid fibril formation by two closely related immunoglobulin light chain variable domains. Amyloid 2010, 17, 129-136.
16. Wilson, M. R.; Yerbury, J. J.; Poon, S. Potential roles of abundant extracellular chaperones in the control of amyloid formation and toxicity. Mole. BioSyst. 2008, 4, 42-52.
17. Ionescu-Zanetti, C.; Khurana, R.; Gillespie, J. R.; Petrick, J. S.; Trabachino, L. C.; Minert, L. J.; Carter, S. A.; Fink, A. L. Monitoring the assembly of Ig light-chain amyloid fibrils by atomic force microscopy. Proc. Natl. Acad. Sci. USA 1999, 96, 13175-13179.
18. Fujita, H.; Hishizawa, M.; Sakamoto, S.; Kondo, T.; Kadowaki, N.; Ishikawa, T.; Itoh, J.; Fukatsu, A.; Uchiyama, T.; Takaori-Kondo, A. Durable hematological response and improvement of nephrotic syndrome on thalidomide therapy in a patient with refractory light chain deposition disease. Int. J. Hematol. 2011, 93, 673-676.
19. Jimenez-Zepeda, V. H. Light chain deposition disease: Novel biological insights and treatment advances. Int. J. Lab. Hematol. 2012, 34, 347-355.
20. Abraham, R. S.; Katzmann, J. A.; Clark, R. J.; Bradwell, A. R.; Kyle, R. A.; Gertz, M. A. Quantitative analysis of serum free light chains. A new marker for the diagnostic evaluation of primary systemic amyloidosis. Am. J. Clin. Pathol. 2003, 119, 274-278.
21. Baden, E. M.; Owen, B. A.; Peterson, F. C.; Volkman, B. F.; Ramirez-Alvarado, M.; Thompson, J. R. Altered dimer interface decreases stability in an amyloidogenic protein. J. Biol. Chem. 2008, 283, 15853-15860.